Roche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown - Fierce Biotech
Roche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown Fierce Biotech
Roche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown Fierce Biotech